泽璟制药(688266.SH)：注射用ZG006治疗晚期神经内分泌癌纳入突破性治疗品种公示名单

Core Viewpoint - Zai Lab's investigational product ZG006 has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) of China, targeting DLL3-positive advanced neuroendocrine carcinoma patients who have previously relapsed or progressed after platinum-based therapy [1] Group 1 - Zai Lab's ZG006 is indicated for the treatment of patients with advanced neuroendocrine carcinoma [1] - The inclusion in the breakthrough therapy list signifies a potential acceleration in the development and review process for ZG006 [1] - The targeted patient population consists of those who have undergone at least one platinum-based treatment and have experienced relapse or progression [1]